130 related articles for article (PubMed ID: 10098284)
1. Differential expression of epidermal growth factor receptor in melanocytic tumours demonstrated by immunohistochemistry and mRNA in situ hybridization.
Sparrow LE; Heenan PJ
Australas J Dermatol; 1999 Feb; 40(1):19-24. PubMed ID: 10098284
[TBL] [Abstract][Full Text] [Related]
2. In situ analysis of transforming growth factor-beta s (TGF-beta 1, TGF-beta 2, TGF-beta 3), and TGF-beta type II receptor expression in malignant melanoma.
Schmid P; Itin P; Rufli T
Carcinogenesis; 1995 Jul; 16(7):1499-503. PubMed ID: 7614683
[TBL] [Abstract][Full Text] [Related]
3. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
Nasr MR; El-Zammar O
Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
[TBL] [Abstract][Full Text] [Related]
4. Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions.
Massi D; Franchi A; Sardi I; Magnelli L; Paglierani M; Borgognoni L; Maria Reali U; Santucci M
J Pathol; 2001 Jun; 194(2):194-200. PubMed ID: 11400148
[TBL] [Abstract][Full Text] [Related]
5. Increased epidermal growth factor receptors in melanocytic lesions.
Ellis DL; King LE; Nanney LB
J Am Acad Dermatol; 1992 Oct; 27(4):539-46. PubMed ID: 1383295
[TBL] [Abstract][Full Text] [Related]
6. The distribution of cellular adhesion molecules in pigmented skin lesions.
van Duinen CM; van den Broek LJ; Vermeer BJ; Fleuren GJ; Bruijn JA
Cancer; 1994 Apr; 73(8):2131-9. PubMed ID: 7512443
[TBL] [Abstract][Full Text] [Related]
7. Differential expression of basic fibroblast growth factor (bFGF) in melanocytic lesions demonstrated by in situ hybridization. Implications for tumor progression.
Reed JA; McNutt NS; Albino AP
Am J Pathol; 1994 Feb; 144(2):329-36. PubMed ID: 8311116
[TBL] [Abstract][Full Text] [Related]
8. Expression of the mast cell growth factor interleukin-3 in melanocytic lesions correlates with an increased number of mast cells in the perilesional stroma: implications for melanoma progression.
Reed JA; McNutt NS; Bogdany JK; Albino AP
J Cutan Pathol; 1996 Dec; 23(6):495-505. PubMed ID: 9001979
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic and prognostic role of galectin 3 expression in cutaneous melanoma.
Abdou AG; Hammam MA; Farargy SE; Farag AG; El Shafey EN; Farouk S; Elnaidany NF
Am J Dermatopathol; 2010 Dec; 32(8):809-14. PubMed ID: 20885286
[TBL] [Abstract][Full Text] [Related]
10. Molecular analysis of melanoma precursor lesions.
Wang Y; Rao U; Mascari R; Richards TJ; Panson AJ; Edington HD; Shipe-Spotloe JM; Donnelly SS; Kirkwood JM; Becker D
Cell Growth Differ; 1996 Dec; 7(12):1733-40. PubMed ID: 8959342
[TBL] [Abstract][Full Text] [Related]
11. Expression of interleukin-8 detected by in situ hybridization correlates with worse prognosis in primary cutaneous melanoma.
Nürnberg W; Tobias D; Otto F; Henz BM; Schadendorf D
J Pathol; 1999 Dec; 189(4):546-51. PubMed ID: 10629556
[TBL] [Abstract][Full Text] [Related]
12. Keratotic melanocytic nevus: a clinicopathologic and immunohistochemical study.
Horenstein MG; Prieto VG; Burchette JL; Shea CR
J Cutan Pathol; 2000 Aug; 27(7):344-50. PubMed ID: 10917161
[TBL] [Abstract][Full Text] [Related]
13. Melanocytic dysplastic naevi occupy the middle ground between benign melanocytic naevi and cutaneous malignant melanomas: emerging clues.
Hussein MR
J Clin Pathol; 2005 May; 58(5):453-6. PubMed ID: 15858113
[TBL] [Abstract][Full Text] [Related]
14. Benign melanocytic lesions: risk markers or precursors of cutaneous melanoma?
Skender-Kalnenas TM; English DR; Heenan PJ
J Am Acad Dermatol; 1995 Dec; 33(6):1000-7. PubMed ID: 7490345
[TBL] [Abstract][Full Text] [Related]
15. Proliferative activity of primary cutaneous melanocytic tumours.
Kuwata T; Kitagawa M; Kasuga T
Virchows Arch A Pathol Anat Histopathol; 1993; 423(5):359-64. PubMed ID: 7906909
[TBL] [Abstract][Full Text] [Related]
16. Nerve growth and expression of receptors for nerve growth factor in tumors of melanocyte origin.
Bröcker EB; Magiera H; Herlyn M
J Invest Dermatol; 1991 May; 96(5):662-5. PubMed ID: 1850772
[TBL] [Abstract][Full Text] [Related]
17. The differential expression of micro-RNAs 21, 200c, 204, 205, and 211 in benign, dysplastic and malignant melanocytic lesions and critical evaluation of their role as diagnostic biomarkers.
Quiohilag K; Caie P; Oniscu A; Brenn T; Harrison D
Virchows Arch; 2020 Jul; 477(1):121-130. PubMed ID: 32388720
[TBL] [Abstract][Full Text] [Related]
18. Macrophage migration inhibitory factor protein and mRNA expression in cutaneous melanocytic tumours.
Miracco C; De Nisi MC; Arcuri F; Cosci E; Pacenti L; Toscano M; Lalinga AV; Biagioli M; Rubegni P; Vatti R; Maellaro E; Del Bello B; Massi D; Luzi P; Tosi P
Int J Oncol; 2006 Feb; 28(2):345-52. PubMed ID: 16391788
[TBL] [Abstract][Full Text] [Related]
19. Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma.
Massi D; Naldini A; Ardinghi C; Carraro F; Franchi A; Paglierani M; Tarantini F; Ketabchi S; Cirino G; Hollenberg MD; Geppetti P; Santucci M
Hum Pathol; 2005 Jun; 36(6):676-85. PubMed ID: 16021575
[TBL] [Abstract][Full Text] [Related]
20. Expression of cytoskeletal components in melanocytic skin lesions. An immunohistochemical study.
Puches R; Smolle J; Rieger E; Soyer HP; Kerl H
Am J Dermatopathol; 1991 Apr; 13(2):137-44. PubMed ID: 2029088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
